An observational study in Acute Ischemic Stroke, sponsored by Ever Neuro Pharma GmbH. Completed at 8 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Ever Neuro Pharma GmbH · Observational
This study investigates the clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with moderate to severe neurological deficits after acute ischemic stroke.
Patients registered: Acute Ischemic Stroke patients with moderate to severe neurological deficits
All patients receive acute stroke care according to local treatment standards, not amended or influenced by the study:
Cerebrolysin Group:
Patients who are treated with Cerebrolysin; dosage, frequency and duration follows local clinical practice in accordance with terms of the local marketing authorization
Control group:
Patients who are not treated with Cerebrolysin
Observation criteria:
The study follows the recommendations of the Principles for Good Research on Comparative Effectiveness (GRACE).
In order to comply with recent calls for high-quality non-interventional comparative effectiveness research, a risk-based centralized statistical approach to monitoring is introduced in combination with targeted on-site monitoring for ongoing surveillance of study conduct, thus ensuring highest standards of data quality and integrity according to the most recent requirements of the ICH E6 Guideline for Good Clinical Practice (GCP, Amendment R2, July 2015), the FDA Guidance for Industry on a Risk-based Approach to Monitoring, and the EMA reflection-paper on risk-based quality management in clinical trials.
Patients with moderate to severe neurological deficits after acute ischemic stroke (NIHSS 8-15) at baseline
Exclusion Criteria:
Drug: Cerebrolysin
Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.
Ordinal modified Rankin Scale (mRS) at 3 months after stroke onset
The modified Rankin Scale scale is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death.
Time frame: 3 months
Ordinal NIH Stroke Scale (NIHSS) at 21 days and 3 months after stroke onset
The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.
Time frame: Day 21 and 3 months
Ordinal modified Rankin Scale (mRS) at 21 days after stroke onset
The modified Rankin Scale scale is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death.
Time frame: 21 days
Proportion of patients with excellent recovery (mRS score 0-1) at 3 months after stroke onset
The modified Rankin Scale scale is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death.
Time frame: 3 months
Proportion of patients with functional independence (mRS score 0-2) at 3 months after stroke onset
The modified Rankin Scale scale is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death.
Time frame: 3 months
Ordinal MoCA at 3 months after stroke
The Montreal Cognitive Assessment (MoCA) is a widely used screening assessment for detecting cognitive impairment. The MoCA test is a one-page 30-point test administered in approximately 10 minutes. MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal.
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ever Neuro Pharma GmbH